Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Drug treatment as HIV prevention: expanding treatment options.

Metzger DS, Zhang Y.

Curr HIV/AIDS Rep. 2010 Nov;7(4):220-5. doi: 10.1007/s11904-010-0059-z. Review.

2.

Drug treatment as HIV prevention: a research update.

Metzger DS, Woody GE, O'Brien CP.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 1:S32-6. doi: 10.1097/QAI.0b013e3181f9c10b. Review.

3.

Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.

Alistar SS, Owens DK, Brandeau ML.

PLoS Med. 2011 Mar;8(3):e1000423. doi: 10.1371/journal.pmed.1000423. Epub 2011 Mar 1.

4.

Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.

Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

Drug Alcohol Depend. 2013 Dec 1;133(2):376-82. doi: 10.1016/j.drugalcdep.2013.06.024. Epub 2013 Jul 31.

5.

Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN; HPTN 058 Protocol Team.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):554-61. doi: 10.1097/QAI.0000000000000510.

6.

Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran.

Farnia M, Ebrahimi B, Shams A, Zamani S.

Int J Drug Policy. 2010 Sep;21(5):422-4. doi: 10.1016/j.drugpo.2010.03.008. Epub 2010 Apr 21. Review.

PMID:
20413287
7.

Opioid treatment in Ukraine risks losing momentum.

[No authors listed]

Bull World Health Organ. 2013 Feb 1;91(2):87-8. doi: 10.2471/BLT.13.020213.

8.

Methadone maintenance as HIV risk reduction with street-recruited injecting drug users.

Kwiatkowski CF, Booth RE.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):483-9.

PMID:
11391170
9.

Mitigating the risk of HIV infection with opioid substitution treatment.

Gowing LR, Hickman M, Degenhardt L.

Bull World Health Organ. 2013 Feb 1;91(2):148-9. doi: 10.2471/BLT.12.109553. Review. No abstract available.

10.

Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.

Bachireddy C, Weisberg DF, Altice FL.

Addiction. 2015 Dec;110(12):1869-71. doi: 10.1111/add.13055. Epub 2015 Oct 13. No abstract available.

PMID:
26464200
11.

Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.

Piralishvili G, Otiashvili D, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

J Subst Abuse Treat. 2015 Mar;50:32-7. doi: 10.1016/j.jsat.2014.10.003. Epub 2014 Oct 22.

PMID:
25456093
12.

Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.

Lucas GM, Beauchamp G, Aramrattana A, Shao Y, Liu W, Fu L, Jackson JB, Celentano DD, Richardson P, Metzger D; HPTN 058 study group.

Int J Drug Policy. 2012 Mar;23(2):162-5. doi: 10.1016/j.drugpo.2011.06.005. Epub 2011 Aug 17.

13.

HIV infection and cocaine use in methadone maintained and untreated intravenous drug users.

Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR.

Drug Alcohol Depend. 1994 Oct;36(2):109-13.

PMID:
7851277
14.
15.

Psychoeducational group approach: HIV risk reduction in drug users.

Sorensen JL, London J, Heitzmann C, Gibson DR, Morales ES, Dumontet R, Acree M.

AIDS Educ Prev. 1994 Apr;6(2):95-112.

PMID:
8018443
16.

Self-efficacy and HIV risk behaviors among heroin users in Taiwan.

Ko NY, Wang PW, Wu HC, Yen CN, Hsu ST, Yeh YC, Chung KS, Yen CF.

J Stud Alcohol Drugs. 2012 May;73(3):469-76.

PMID:
22456252
17.

Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: a mathematical modeling study.

Wammes JJ, Siregar AY, Hidayat T, Raya RP, van Crevel R, van der Ven AJ, Baltussen R.

Int J Drug Policy. 2012 Sep;23(5):358-64. doi: 10.1016/j.drugpo.2012.06.009. Epub 2012 Aug 10.

18.

Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.

Ayres R, Ingram J, Rees A, Neale J, Beattie A, Telfer M.

Subst Abuse Treat Prev Policy. 2014 Nov 18;9:44. doi: 10.1186/1747-597X-9-44.

19.

Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.

Carrieri MP, Roux P, Cohen J, Ravaux I, Dellamonica P, Protopopescu C, Spire B, Rosenblum A.

Addiction. 2010 Dec;105(12):2160-8. doi: 10.1111/j.1360-0443.2010.03108.x. Epub 2010 Sep 15.

PMID:
20840169
20.

Pharmacological interventions for drug-using offenders.

Perry AE, Neilson M, Martyn-St James M, Glanville JM, Woodhouse R, Godfrey C, Hewitt C.

Cochrane Database Syst Rev. 2015 Jun 2;(6):CD010862. doi: 10.1002/14651858.CD010862.pub2. Review.

PMID:
26035084

Supplemental Content

Support Center